SCHEMBL3911053

SCHEMBL3911053

Cc1ccc(C(=O)N(C)Cc2ccc(Cl)cc2Cl)c(NS(=O)(=O)C2=CC=CN3SNC=C23)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
CCKBR P32239 2/20 0.37
ACLY P53396 1/20 0.34
CCKAR P32238 1/20 0.33
GCGR P47871 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
FLT1 P17948 2/20 0.31
FLT4 P35916 2/20 0.31
KDR P35968 2/20 0.31
METAP2 P50579 1/20 0.31
PCTP Q9UKL6 1/20 0.30
STARD10 Q9Y365 1/20 0.30
ALDH1A1 P00352 1/20 0.30
GAA P10253 1/20 0.30
HTT P42858 1/20 0.30
EPHX2 P34913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3901168 0.95 CRHBP (0.40) CRHBPCRHR2CCKBRCCKARGCGR
SCHEMBL3907638 0.93 KMT2A (0.34) CRHBPCRHR2CCKBRACLYMEN1
SCHEMBL3905799 0.92 CRHBP (0.38) CRHBPCRHR2CCKBRCCKARGCGR
SCHEMBL3905812 0.92 CRHBP (0.38) CRHBPCRHR2CCKBRCCKARGCGR
SCHEMBL3906684 0.91 CRHBP (0.39) CRHBPCRHR2CCKBRCCKARGCGR
SCHEMBL3896931 0.91 CRHBP (0.40) CRHBPCRHR2CCKBRACLYGCGR
SCHEMBL3902440 0.90 CCKBR (0.38) CRHBPCRHR2CCKBRCCKARMEN1
SCHEMBL3899767 0.87 KMT2A (0.35) MEN1KMT2A
SCHEMBL3903734 0.87 EPHX2 (0.37) CCKBRACLYFLT1FLT4KDR
SCHEMBL3906317 0.86 CCR2 (0.39) CRHBPCRHR2CCKBRCCKARMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7550492-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-23 US disclosed
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-29 US disclosed
US-7241759-B2 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-10 US disclosed
EP-1675837-A2 BENZO [1,2,5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-05 EP disclosed
WO-2005012275-A2 BENZO [1, 2, 5] THIADIAZOLE COMPOUNDS AS CCK2 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-10 WO disclosed
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds JANSSEN PHARMACEUTICA, N.V. (BE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276016-A1 BENZO[1,2,5]THIADIAZOLE COMPOUNDS CCKBR, CCKAR, GIPR CRHBP 784/4885CRHR2 60/4885CCKBR 1/4885
US-20040224983-A1 Benzo[1,2,5]thiadiazole compounds CCKBR, CCKAR, BRSK2 CRHBP 956/4885CRHR2 61/4885CCKBR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.